Image

Global Pneumonia Therapeutics Market – Industry Trends and Forecast to 2030

Pharmaceutical

Image

Global Pneumonia Therapeutics Market – Industry Trends and Forecast to 2030

  • Pharmaceutical
  • Upcoming Report
  • Nov 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Pneumonia Therapeutics Market – Industry Trends and Forecast to 2030

Market Size in USD Billion

CAGR :  % Diagram

Diagram Forecast Period 2022–2030
Diagram Market Size (Base Year) USD 2.15 USD Billion
Diagram Market Size (Forecast Year) USD 4.00 USD Billion
Diagram CAGR %

Major Markets Players

  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

Global Pneumonia Therapeutics Market, By Infection Type (Hospital-acquired Pneumonia [HAP], Community-acquired Pneumonia [CAP], Ventilator-associated Pneumonia [VAP]), Drug Class (Antibacterial Drugs, Antiviral DrugsAntifungal Drugs), By Age Group (Paediatric, Adult, Geriatric), Type (Drugs, Preventive Vaccines, Oxygen Therapy), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.

Pneumonia Therapeutics Market

 Pneumonia Therapeutics Market Analysis and Size

Pneumonia is caused by bacteria, fungi or viruses and results for 5% of deaths among children below 5 years of age. Incidence of pneumonia is considerably high in paediatric population of African countries. Though, lack of accessibility to pneumonia therapeutics and treatment facilities has kept death rate higher in African countries. Rising prevalence of community-acquired pneumonia, especially in younger individuals, is also a major factor contributing to market growth

 Data Bridge Market Research analyses a growth rate in the pneumonia therapeutics market in the forecast period 2023-2030. The expected CAGR of hypophosphatemia treatment market is around 8.1% in the mentioned forecast period. The market was valued at USD 2.15 billion in 2022, and it would grow upto USD 4 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Pneumonia Therapeutics Market Scope and Segmentation

Report Metric

Details

Forecast Period

2023 to 2030

Base Year

2022

Historic Years

2021 (Customizable to 2015 - 2020)

Quantitative Units

Revenue in USD Billion, Volumes in Units, Pricing in USD

Segments Covered

Infection Type (Hospital-acquired Pneumonia [HAP], Community-acquired Pneumonia [CAP], Ventilator-associated Pneumonia [VAP]) Drug Class (Antibacterial Drugs, Antiviral Drugs, Antifungal Drugs), By Age Group (Paediatric, Adult, Geriatric), Type (Drugs, Preventive Vaccines, Oxygen Therapy), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

AstraZeneca (U.K.), Lilly (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Novartis AG (Switzerland), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), Merck & Co., Inc. (U.S.), Pfizer Inc. (U.S.), GSK plc (U.K.), Hikma Pharmaceuticals PLC (U.K.), Cipla Inc. (India), Lupin (India)

Market Opportunities

  • Rising Clinical Trial Activities
  • Increasing Strategies by Several Market Players

Market Definition

Pneumonia is an inflammatory medical condition that affects the air sacs and alveoli in the lungs. Pathogens such as bacteria, virus and fungi are causing the pneumococcal infection through inhalation of air borne droplets from sneeze or cough. It can also be caused by contact with objects and surfaces contaminated with pneumonia causing bacteria and virus. According to WHO, the annual incidence is around 150.7 million cases, of which 7% to 13% require intensive treatment.

Global Pneumonia Therapeutics Market Dynamics

Drivers

  • Rising Demand of Antiviral Drugs

Viral pneumonia spreads through fluid present in the air droplets after an individual coughs or sneezes. These fluids enter into the body through mouth or nose. Numerous treatment options such as  oseltamivir and acyclovir among others are used to treat the antiviral infection. Likewise, these drugs help reduce the severity of flu virus spreading into the body, further enhancing the market progression. Thus, the more and more consumption of antiviral drugs acts as a major driver of growth in the global pneumonia therapeutics market.

  • Growing number of hospital-acquired pneumonia infections

Hospital-acquired pneumonia is a lung infection which occurs during hospital stays. Majority of patients with hospital-acquired pneumonia develop severe complications that include renal failure, respiratory failure and empyema because of severe and weak health conditions. Thus, increasing occurrences of hospital-acquired pneumonia will increase the demand for pneumonia therapeutics drugs.

Opportunities

  • Rising Clinical Trial Activities

Growing number of on-going clinical trials for the development of drug molecules will have a major impact on the market progression. For instance, in February 2020, FDA accepted the review supplemental new drug application for Recarbrio for the treatment of adults with ventilator-associated and hospital-acquired bacterial pneumonia. Launching several new drug molecules will increase the market growth during the forecast timeframe. Thus, this increase the market growth.

  • Increasing Strategies by Several Market Players

Market players are undertaking numerous organic and inorganic growth strategies to capture an increasing market share in pneumonia therapeutics. For instance, in September 2018, Pfizer received breakthrough therapy designation from the U.S. FDA for its 20-Valent Pneumococcal Conjugate Vaccine. This vaccine is helpful for the prevention of pneumonia and invasive disease. This strategy improved the company’s product portfolio.

 Restraints/Challenges

  • Lack of skilled professionals

The lack of trained healthcare professionals who cannot treat the patients with appropriate treatments could limit the growth of the global pneumonia therapeutics market during a forecast period.

  • High Cost For Drug Development

The current treatment options for pneumonia therapeutics are limited to antibiotics, and numerous pharmaceutical companies are presently focusing on developing non-antibiotic alternatives. Developing a new class of drugs will offer many growth opportunities for key players, but it will also essentially require major investments in R&D activities of novel therapies. The considerably high investment requirements may act as an obstacle to market growth.  

This pneumonia therapeutics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the pneumonia therapeutics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Pneumonia Therapeutics Market       

COVID-19 has largely impacted and could continue to impact other companies' businesses, including their preclinical trials and clinical trials of microbiome-based therapeutics and diagnostic products. The global pneumonia therapeutics market is projected to prosper exponentially in the upcoming years mainly because of the increasing cases of transmitted diseases and growing elderly population with weak immune system. In addition to this, increasing research and development activities by several market players in the development of medications and therapeutic agents is also estimated to increase the market growth during the 2023-2030. For instance, the King of Prussia biopharma firm’s pneumonia drug ‘Nabriva’ recently got marketing approval from the European government for the treatment of community-acquired pneumonia in adults.

Recent Development

  • In June 2019, Merck received FDA approval for the Zerbaxa drug used to treat ventilator-associated pneumonia and hospital-acquired bacterial pneumonia. This strategy expanded the firm’s pneumonia therapeutics portfolio.

Global Pneumonia Therapeutics Market Scope

The pneumonia therapeutics market is segmented on the basis of drug class, age group, type, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug Class

  • Antibacterial Drugs
  • Macrolide
  • Quinolones
  • Antiviral Drugs
  • Oseltamivir phosphate
  • Zanamivir
  • Antifungal Drugs
  • Clotrimazole
  • Econazole

Age Group

  • Paediatric
  • Adult
  • Geriatric

Infection Type

  • Hospital-acquired Pneumonia [HAP]
  • Community-acquired Pneumonia [CAP]
  • Ventilator-associated Pneumonia [VAP]

Type

  • Drugs
  • Preventive Vaccines
  • Oxygen Therapy

Route of Administration

  • Oral
  • Parenteral
  • Others

End User

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

Pneumonia Therapeutics Market Regional Analysis/Insights

The pneumonia therapeutics market is analyzed and market size insights and trends are provided by drug class, age group, type, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the pneumonia therapeutics market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America has been witnessing a positive growth for pneumonia therapeutics market throughout the forecasted period due to the presence of geriatric population and increased healthcare facility.  

Asia-Pacific dominates the market due to increased manufacturers of pharmaceuticals and vaccines in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Pneumonia Therapeutics Market Share Analysis

The pneumonia therapeutics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to pneumonia therapeutics market.

Key players operating in the pneumonia therapeutics market include:

  • AstraZeneca (U.K.)
  • Lilly (U.S.)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Mylan N.V. (U.S.)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Sanofi (France)
  • Novartis AG (Switzerland)
  • Sun Pharmaceutical Industries Ltd. (India)
  • Aurobindo Pharma (India)
  • Lupin (India)
  • Merck & Co., Inc. (U.S.)
  • Pfizer Inc. (U.S.)
  • GSK plc (U.K.)
  • Hikma Pharmaceuticals PLC (U.K.)
  • Cipla Inc. (India)
  • Lupin (India) 


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

FREQUENTLY ASK QUESTIONS

The pneumonia therapeutics market size will be worth USD 4 billion by 2030.
The growth rate of the pneumonia therapeutics market is 8.1% in the forecast by 2030.
The major companies in the pneumonia therapeutics market are AstraZeneca (U.K.), Lilly (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Novartis AG (Switzerland), etc.
Drug class, age group, type, distribution channel and end-user are the factors on which the pneumonia therapeutics market research is based.
Rising demand of antiviral drugs & growing number of hospital-acquired pneumonia infections are the growth drivers of the pneumonia therapeutics market.
Free Sample Report

CHOOSE LICENCE TYPE

  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials